Novartis Accepts its First Delivery from GeneProt of Six Synthetic Proteins | GenomeWeb

For the first time in their 14 month-old research partnership, Novartis has accepted six of GeneProt’s synthetic proteins for further drug development, the two companies said December 20.

The six proteins Novartis selected represent about half of the number of proteins GeneProt has presented to Novartis, said Cédric Loiret-Bernal, CEO of GeneProt. “We have more proteins but only six have been accepted,” he said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.